… provides a regulatory viewpoint on transporters and their potential role in drug–drug interactions.
It … This commentary therefore provides a regulatory viewpoint on transporters and their …

… scientific literature evaluating the interaction potential of … drug interaction liability is presented.
This review also highlights the regulatory science viewpoint on botanical–drug interactions …

… for drug-drug interactions. The chapters in this book present a comprehensive review of the
scientific and regulatory aspects of drug-drug interactions … The topics covered include drug …

… to guide further in vivo drug interaction studies and to … drug interaction potential during
drug development and uses a case study to highlight the impact of in vitro information on drug …

… intestinal DDIs; however, EMEA regulation suggests that the assessment of intestinal DDIs
for CYP3A inhibitors should be performed if the drug is orally administered. No report has …

… predicting drug interactions based on in vitro evaluations, unexpected drug−drug interactions
do … Collectively, these interactions may be defined as “complex drug interactions” including …

… in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (…
by regulatory agencies in compound registration dossiers. Drug-drug interactions can lead to …

… regulation is larger in scope compared to the United States. Returning to the example of CDS
for drug-drug interactions… the United States and stringent regulation in Europe can lead to …

… Drug-drug interactions (DDI) are key aspects of drug metabolism and pharmacokinetic
considerations and are studied in both preclinical development and throughout the clinical …

… Drug interactions in patients receiving multiple drug regimens … of new drugs and their
concomitant use with other drugs, there … viewpoint, considering different drug treatments in a drug …